The global breast lesion localization market revenue was around US$ 316.4 million in 2022 and is estimated to reach US$ 516.7 million by 2031, growing at a compound annual growth rate (CAGR) of 5.6% during the forecast period from 2023 to 2031.
A breast lesion or injury is an uncommon change in breast tissue caused by injury or disease. A benign lesion is non-cancerous, whereas a malignant lesion is cancerous. Breast lumps are frequently reported by women of all ages. Breast lumps can also generate modifications in the shape of the breast and pain.
Market Driving Factors
The increasing prevalence of breast cancer among people, along with organizational initiatives to tackle breast cancer cases drive the market growth. The diagnosis rates of breast cancer have particularly risen over the past few decades due to imaging and other mammography tools, but methods for localizing breast lesions have remained undamaged. Furthermore, localization techniques are now needed in up to 50% of all surgical biopsy and lumpectomy procedures to ensure proper removal of the target lesion owing to early diagnosis of breast lesions.
Developing countries such as China, India, Mexico, Brazil, and Colombia offer lucrative opportunities for industry participants in the market. More individuals are relocating to cities as these nations' urbanization accelerates. This has encouraged the corporate and government sectors to finance in extending their healthcare infrastructure. As a result, private hospitals finance heavily on new technology to attract more patients and advantages from the existing shortfall in public healthcare.
The high price associated with breast cancer treatment and breast lesion localization devices hamper the market growth.
Regional Analysis
Europe dominated the market in terms of the growth rate. This can be attributed to the surge in the incidence of breast cancer and the adoption of cutting-edge localization techniques for the treatment of Breast Cancer, leading to an augmented rate of Breast cancer patients in the nations of this region.
North America is expected to dominate the market in terms of the largest shares. This is due to the availability of the government’s organized cancer screening programs and reimbursement policies availability in the region. Furthermore, a maximum number of the population suffers from breast cancer and the government is creating massive investments in medical requirements and breast lesion localization devices. These elements are contributing to the market growth.
Segmentation Insights
Type Insight
The electromagnetic localization segment is estimated to dominate the market. This is due to its higher ability to detect breast lesions among the patients, which aids the surgeon in an adequate treatment procedure with patient safety. Furthermore, the increasing innovations in electromagnetic localization technologies, like wireless breast lesion localization systems, enable discomfort for patients and limit the requirement for physical wires that are attached to the body.
Usage Insight
The breast conservation segment accounted for the largest share of the market. The surrounding and malignancy tissue is removed during breast-conserving surgery. The goal is to minimize the chance of cancer recurrence while removing precisely the right amount of tissue to allow the breast to heal from surgery appearing as natural. Patients' desires to maintain the form and appearance of their breasts are the main factors for segment growth.
The breast biopsy segment is estimated to dominate the fastest growth in the market. This is due to the enhanced precision of the diagnosis. A biopsy involves taking a small sample of tissue and having it evaluated in a lab. A special biopsy needle can be used to remove breast tissue for a breast biopsy. It could potentially be surgically removed. It is examined to determine whether it includes cancerous or other aberrant cells.
End User Insight
The ambulatory surgical centers segment dominates the market. It is highly influenced by the continuous increase in minimally invasive procedures. The increasing concerns about breast-related health problems like breast cancer among individuals are encouraging them to go into early detection centers like ambulatory surgical centers and driving surgeons to utilize breast lesion localization procedures for different treatments.
Prominent Companies
Segmentation Outline
The global breast lesion localization market segmentation focuses on Type, Usage, End User, and Region.
By Type
By Usage
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL BREAST LESION LOCALIZATION MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: BREAST LESION LOCALIZATION MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL BREAST LESION LOCALIZATION MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL BREAST LESION LOCALIZATION MARKET, BY TYPE
5.1 OVERVIEW
5.2 WIRE LOCALIZATION
5.3 RADIOISOTOPE LOCALIZATION
5.4 MAGNETIC LOCALIZATION
5.5 ELECTROMAGNETIC LOCALIZATION
5.6 OTHERS
6 GLOBAL BREAST LESION LOCALIZATION MARKET, BY USAGE
6.1 OVERVIEW
6.2 BREAST BIOPSY
6.3 BREAST CONSERVATION (LUMPECTOMY)
7 GLOBAL BREAST LESION LOCALIZATION MARKET, BY END USER
7.1 OVERVIEW
7.2 HOSPITALS & CLINICS
7.3 DIAGNOSTIC IMAGING CENTERS
7.4 AMBULATORY SURGICAL CENTERS
7.5 OTHERS
8 GLOBAL BREAST LESION LOCALIZATION MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL BREAST LESION LOCALIZATION MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 AMBU
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 ARGON MEDICAL
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 BIOMEDICAL SRL
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 BPB MEDICA
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 DRAGERWERK
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 ELUCENT MEDICAL
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 ENDOMAGNETICS
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 GE HEALTHCARE
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 HOLOGIC
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 INTRAMEDICAL IMAGING
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 ISOAID
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 IZI MEDICAL PRODUCTS
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 KONINKLIJKE PHILIPS N.V.
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 LAURANE MEDICAL
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 MATEK MEDIKAL
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.16 M.D.L SRL
10.16.1 OVERVIEW
10.16.2 FINANCIAL PERFORMANCE
10.16.3 PRODUCT OUTLOOK
10.16.4 KEY DEVELOPMENTS
10.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved